Increased skin flap viability after treatment with forskolin or with ridogrel, a thromboxane synthesis inhibitor and receptor blocker.
Two ventral skin flaps were raised in each of 60 rats and viability was assessed 48 h after operation. Twenty animals served as controls and immediately preoperatively 20 received an intraperitoneal injection of either 5 mg/kg body weight ridogrel, a combined thromboxane synthesis inhibitor and receptor blocker, or 4 mg/kg forskolin, a cAMP stimulator. The mean total and surviving flap areas measured 14.3 +/- 1.4 and 10.1 +/- 3.2 cm2 respectively for the control group. In the treated groups it was 16.4 +/- 1.3 cm2 and 15.6 +/- 2.6 cm2 for ridogrel and 17.8 +/- 1.1 cm2 and 15.8 +/- 4.3 cm2 for forskolin respectively. The differences between the areas of each treated group and the control group were statistically significant (p less than 0.0001). It can be concluded that both ridogrel and forskolin afford protection against skin necrosis probably because of improved conditions in the microcirculation due to reduced platelet aggregation in the vasculature of the distal part of the flap.
Banić
A
A
Department of Surgery, Faculty of Medicine, Kuwait University, Safat.
Kouris
K
K
Rajacić
N
N
Nazal
M
M
Thulesius
O
O
D000818:Animals; D005576:Colforsin / Q000494:pharmacology*; D006085:Graft Survival; D008297:Male; D008833:Microcirculation; D010421:Pentanoic Acids / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors*; D017482:Receptors, Thromboxane; D012867:Skin / Q000098:blood supply / Q000473:pathology*; D013524:Surgical Flaps / Q000473:pathology*; D013928:Thromboxane A2 / Q000096:biosynthesis; D014631:Valerates / Q000494:pharmacology*
D010421:Pentanoic Acids; D011725:Pyridines; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D014631:Valerates; D005576:Colforsin; D013928:Thromboxane A2; C060219:ridogrel